Spero therapeutics announces lifting of fda clinical trial hold on spr720

Cambridge, mass., jan. 04, 2022 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), today announced that the u.s. food and drug administration (fda) has lifted the clinical hold on the phase 2 trial of spr720, spero's investigational oral product candidate being developed for nontuberculous mycobacterial (ntm) disease.
SPRO Ratings Summary
SPRO Quant Ranking